Brent Logan, PhD

Brent R. Logan, PhD

Director & Professor

Locations

Biostatistics

Contact Information

Education

PhD, Northwestern University, Evanston, IL, 2001
MS, Northwestern University, Evanston, IL, 1998
BS, Vanderbilt University, Nashville, TN, 1996

Research Experience

Multiple Comparison Procedures

Research Interests

Dr. Brent Logan joined the Division of Biostatistics in the Summer of 2001. He has methodological research interests in multiple comparison procedures, clinical trial design, and survival analysis. Research in multiple testing includes methods for analyzing multiple endpoints in clinical trials, analysis of dose-response studies, and multiplicity adjustment in functional MRI studies. His interests in clinical trial design include randomized phase 2 clinical trials and biologic assignment trials in bone marrow transplant studies. Recent work in survival analysis has focused on inference for competing risks and multistate models using pseudo-value regression, analysis in the presence of crossing survival curves, and methods for the analysis of complex bone marrow transplant data. He is a biostatistician for the Blood and Marrow Transplant Clinical Trials Network (BMTCTN) and the Center for International Blood and Marrow Transplant Research (CIBMTR), as well as a statistical consultant for the National Marrow Donor Program.

Curriculum Vitae

Chronic Granulomatous Disease-Associated IBD Resolves and Does Not Adversely Impact Survival Following Allogeneic HCT.

(Marsh RA, Leiding JW, Logan BR, Griffith LM, Arnold DE, Haddad E, Falcone EL, Yin Z, Patel K, Arbuckle E, Bleesing JJ, Sullivan KE, Heimall J, Burroughs LM, Skoda-Smith S, Chandrakasan S, Yu LC, Oshrine BR, Cuvelier GDE, Thakar MS, Chen K, Teira P, Shenoy S, Phelan R, Forbes LR, Chellapandian D, Dávila Saldaña BJ, Shah AJ, Weinacht KG, Joshi A, Boulad F, Quigg TC, Dvorak CC, Grossman D, Torgerson T, Graham P, Prasad V, Knutsen A, Chong H, Miller H, de la Morena MT, DeSantes K, Cowan MJ, Notarangelo LD, Kohn DB, Stenger E, Pai SY, Routes JM, Puck JM, Kapoor N, Pulsipher MA, Malech HL, Parikh S, Kang EM, submitted on behalf of the Primary Immune Deficiency Treatment Consortium.) J Clin Immunol. 2019 Oct;39(7):653-667.
Kinetics of immune cell reconstitution predict survival in allogeneic bone marrow and G-CSF-mobilized stem cell transplantation.

(Waller EK, Logan BR, Fei M, Lee SJ, Confer D, Howard A, Chandrakasan S, Anasetti C, Fernando SM, Giver CR.) Blood Adv. 2019 Aug 13;3(15):2250-2263.
Regarding Recipients Receiving Better HLA-Matched Hematopoietic Cell Transplantation Grafts, Uncovered by a Novel HLA Typing Method, Have Superior Survival: A Retrospective Study.

(Hurley CK, Spellman S, Dehn J, Barker JN, Devine S, Fernandez-Vina M, Gautreaux M, Logan B, Maiers M, Mueller C, Perales MA, Yu N, Pidala J.) Biol Blood Marrow Transplant. 2019 Aug;25(8):e268-e269.
Allogeneic Hematopoietic Cell Transplant for HIV Patients with Hematologic Malignancies: the BMT CTN-0903/AMC-080 Trial.

(Ambinder RF, Wu J, Logan B, Durand CM, Shields R, Popat UR, Little RF, McMahon DK, Cyktor J, Mellors JW, Ayala E, Kaplan LD, Noy A, Jones RJ, Howard A, Forman SJ, Porter D, Arce-Lara C, Shaughnessy P, Sproat L, Hashmi SK, Mendizabal AM, Horowitz MM, Navarro WH, Alvarnas JC.) Biol Blood Marrow Transplant. 2019 Jul 04.
The Concentration of Total Nucleated Cells in Harvested Bone Marrow for Transplantation Has Decreased over Time.

(Prokopishyn NL, Logan BR, Kiefer DM, Sees JA, Chitphakdithai P, Ahmed IA, Anderlini PN, Beitinjaneh AM, Bredeson C, Cerny J, Chhabra S, Daly A, Diaz MA, Farhadfar N, Frangoul HA, Ganguly S, Gastineau DA, Gergis U, Hale GA, Hematti P, Kamble RT, Kasow KA, Lazarus HM, Liesveld JL, Murthy HS, Norkin M, Olsson RF, Papari M, Savani BN, Szer J, Waller EK, Wirk B, Yared JA, Pulsipher MA, Shah NN, Switzer GE, O'Donnell PV, Confer DL, Shaw BE.) Biol Blood Marrow Transplant. 2019 Jul;25(7):1325-1330.
Higher Risks of Toxicity and Incomplete Recovery in 13- to 17-Year-Old Females after Marrow Donation: RDSafe Peds Results.

(Pulsipher MA, Logan BR, Kiefer DM, Chitphakdithai P, Riches ML, Rizzo JD, Anderlini P, Leitman SF, Varni JW, Kobusingye H, Besser RM, Miller JP, Drexler RJ, Abdel-Mageed A, Ahmed IA, Ball ED, Bolwell BJ, Bunin NJ, Cheerva A, Delgado DC, Dvorak CC, Gillio AP, Hahn TE, Hale GA, Haight AE, Hayes-Lattin BM, Kasow KA, Linenberger M, Magalhaes-Silverman M, Mori S, Prasad VK, Quigg TC, Sahdev I, Schriber JR, Shenoy S, Tse WT, Yanik GA, Navarro WH, Horowitz MM, Confer DL, Shaw BE, Switzer GE.) Biol Blood Marrow Transplant. 2019 May;25(5):955-964.
Transplant center practices for psychosocial assessment and management of pediatric hematopoietic stem cell donors.

(Wiener L, Hoag JA, Pelletier W, Shah NN, Shaw BE, Pulsipher MA, Bruce J, Bader P, Willasch AM, Dalissier A, Guilcher G, Anthias C, Confer DL, Sees JA, Logan B, Switzer GE.) Bone Marrow Transplant. 2019 Apr 10.
Moving Toward a Consensus DSC-MRI Protocol: Validation of a Low-Flip Angle Single-Dose Option as a Reference Standard for Brain Tumors.

(Schmainda KM, Prah MA, Hu LS, Quarles CC, Semmineh N, Rand SD, Connelly JM, Anderies B, Zhou Y, Liu Y, Logan B, Stokes A, Baird G, Boxerman JL.) AJNR Am J Neuroradiol. 2019 Apr;40(4):626-633.
Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203).

(Bolaños-Meade J, Reshef R, Fraser R, Fei M, Abhyankar S, Al-Kadhimi Z, Alousi AM, Antin JH, Arai S, Bickett K, Chen YB, Damon LE, Efebera YA, Geller NL, Giralt SA, Hari P, Holtan SG, Horowitz MM, Jacobsohn DA, Jones RJ, Liesveld JL, Logan BR, MacMillan ML, Mielcarek M, Noel P, Pidala J, Porter DL, Pusic I, Sobecks R, Solomon SR, Weisdorf DJ, Wu J, Pasquini MC, Koreth J.) Lancet Haematol. 2019 Mar;6(3):e132-e143.
The Hematopoietic Cell Transplant Comorbidity Index predicts survival after allogeneic transplant for nonmalignant diseases.

(Thakar MS, Broglie L, Logan B, Artz A, Bunin N, Burroughs LM, Fretham C, Jacobsohn DA, Loren AW, Kurtzberg J, Martinez CA, Mineishi S, Nelson AS, Woolfrey A, Pasquini MC, Sorror ML.) Blood. 2019 02 14;133(7):754-762.
Learning the Dynamic Treatment Regimes from Medical Registry Data through Deep Q-network.

(Liu N, Liu Y, Logan B, Xu Z, Tang J, Wang Y.) Sci Rep. 2019 Feb 06;9(1):1495.
Nonparametric competing risks analysis using Bayesian Additive Regression Trees.

(Sparapani R, Logan BR, McCulloch RE, Laud PW.) Stat Methods Med Res. 2019 Jan 07:962280218822140.